WO2005092322A1 - Rar活性化を起こす天然化合物 - Google Patents
Rar活性化を起こす天然化合物 Download PDFInfo
- Publication number
- WO2005092322A1 WO2005092322A1 PCT/JP2005/003601 JP2005003601W WO2005092322A1 WO 2005092322 A1 WO2005092322 A1 WO 2005092322A1 JP 2005003601 W JP2005003601 W JP 2005003601W WO 2005092322 A1 WO2005092322 A1 WO 2005092322A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- rar
- compound
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a compound having retinoic acid-like physiological activity.
- Retinoic acid (vitamin A acid) is an active metabolite of vitamin A. It acts to differentiate developing immature cells into mature cells having unique functions, promotes cell growth, and promotes life. It has extremely important physiological effects such as maintenance. Also, various vitamin A derivatives having the same physiological action as retinoic acid have been synthesized so far. Retinoic acid and compounds having retinoic acid-like biological activity are collectively referred to as retinoids.
- Retinoic acid binds as a ligand to the retinoic acid receptor (RAR) belonging to the nuclear receptor 1 'superfamily (Evans, RM, Science, 240, pp.889-895, 1988) present in the cell nucleus. It has been shown to control animal cell proliferation and cell death or cell death (Petkovich, M., et al., Nature, 330, pp. 444-450, 1987). A compound having a retinoic acid-like biological activity also binds to the RAR and exerts a physiological activity similarly to retinoic acid.
- RAR retinoic acid receptor
- Retinoids have been found to be clinically useful for the treatment and prevention of vitamin A deficiency, keratosis of epithelial tissue, rheumatism, delayed allergy, bone disease, leukemia and certain cancers.
- RAR consists of three subtypes, of which RAR
- RAR o has been reported to have an effect of promoting stagnation in acute preosteoblastic leukemia
- RAR y has been reported to have an effect of treating millet.
- retinoids have been approved for oral treatment of psoriasis and for promyelocytic leukemia.
- retinoids have various biological activities, the viewpoint of side effects (for example, elevation of triglycerides, skin inflammation, etc.) is not necessarily a satisfactory drug. Therefore, creation of a retinoid having a characteristic action and a control molecule thereof has been desired. For example, when focusing on the anticancer effect, a compound having high binding to RAR
- An object of the present invention is to provide a novel compound having retinoic acid-like biological activity, and more specifically, a compound having a novel skeleton different from conventional retinoids. Accordingly, it is an object of the present invention to provide a compound having a characteristic retinoic acid-like activity.
- the present invention provides a compound represented by the following general formula (1) as a novel retinoid.
- R is the same or different and represents a hydrogen atom, an acyl group, an alkyl group, an alkenyl group, an alkynyl group, or an aryl group.
- X represents a benzyl group, a phenylethyl group, a phenylpropyl group.
- An alkylphenol group such as a phenyl group, and a prenyl group such as a 2,2-dimethylaryl group, a geral group, a phenylesyl group, a geralylgeralyl group, and a phytyl group.
- the compounds of the present invention also include pharmaceutically acceptable salts such as sodium, potassium, magnesium, calcium and the like.
- FIG. 1 shows the results of a reporter gene assay showing the RAR activity of each test compound.
- the compound of the present invention has a retinoid-like biological action, for example, a cell differentiation action, a cell growth promoting action, a life sustaining action, and the like, and includes vitamin A deficiency, keratosis of epithelium, psoriasis, It can be used as an active ingredient of a medicament for the prevention or treatment of allergic diseases, immunological diseases such as rheumatism, bone diseases, leukemia, or cancer.
- the medicament capable of acting as a compound of the present invention may be administered as such, but is preferably administered as an oral or parenteral dosage form which can be produced by a method well known to those skilled in the art. .
- Dosage forms suitable for oral administration include, for example, tablets, capsules, powders, fine granules, granules, liquids, and syrups
- dosage forms suitable for parenteral administration include, for example, Examples include injections, suppositories, inhalants, eye drops, nasal drops, ointments, creams, patches and the like.
- the above dosage form can be produced by adding pharmacologically and pharmaceutically acceptable additives.
- pharmacologically and pharmaceutically acceptable additives include, for example, excipients, disintegrants or disintegration aids, binders, lubricants, coatings, pigments, diluents, bases, agents or dissolving aids, isotonic agents, P H adjusting agents, stabilizers, propellants, and may be mentioned an adhesive or the like.
- the dose of the compound of the present invention is usually 110 mg / kg of body weight, preferably 5-20 mg / kg of body weight.
- the administration subject is a mammal, usually a human
- a test compound was added to the culture solution of the cells into which the above plasmid had been introduced. About 40 hours later, the medium was removed and the cells were washed with PBS, and then the fluorescence of EYFP and ECFP was measured. In order to correct the efficiency of introduction of the plasmid into the cells, the fluorescence value of EYFP was corrected using the fluorescence value of ECFP measured as an internal standard. That is, the transcription activity of FXR was evaluated based on the value of (fluorescence value of EYFP) I (fluorescence value of ECFP).
- Caffeic acid phenethyl ester in which R is H and X is phenylethyl in formula (1) has a high activity against RAR jS and is a therapeutic agent for malignant tumors (such as lung cancer). As expected.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511413A JP4904498B2 (ja) | 2004-03-29 | 2005-03-03 | Rar活性化を起こす天然化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-094321 | 2004-03-29 | ||
JP2004094321 | 2004-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005092322A1 true WO2005092322A1 (ja) | 2005-10-06 |
Family
ID=35055968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003601 WO2005092322A1 (ja) | 2004-03-29 | 2005-03-03 | Rar活性化を起こす天然化合物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4904498B2 (ja) |
WO (1) | WO2005092322A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011178762A (ja) * | 2010-03-04 | 2011-09-15 | Pola Chemical Industries Inc | メラニン産生抑制剤 |
WO2021053493A1 (en) * | 2019-09-17 | 2021-03-25 | Enzene Biosciences Limited | Compositions for use in inhibiting src kinase and treating and preventing associated disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11503111A (ja) * | 1995-02-17 | 1999-03-23 | アメリカ合衆国 | ヒドロキシル化芳香族のタンパク質架橋性化合物の局所塗布による、上皮過増殖症の治療法 |
JP2001523085A (ja) * | 1996-09-05 | 2001-11-20 | リサーチ ディベロップメント ファンデーション | カフェイン酸フェネチル・エステル(CAPE)、CAPEの誘導体、カプサイシン(8―メチル―N―バニリル―6―ノネンアミド)及び樹脂分泌毒素による核転写ファクターNF―κBの抑制 |
JP2003524577A (ja) * | 1997-10-31 | 2003-08-19 | アーチ・デヴェロップメント・コーポレイション | 5α−還元酵素活性を調節するための方法及び組成物 |
-
2005
- 2005-03-03 JP JP2006511413A patent/JP4904498B2/ja active Active
- 2005-03-03 WO PCT/JP2005/003601 patent/WO2005092322A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11503111A (ja) * | 1995-02-17 | 1999-03-23 | アメリカ合衆国 | ヒドロキシル化芳香族のタンパク質架橋性化合物の局所塗布による、上皮過増殖症の治療法 |
JP2001523085A (ja) * | 1996-09-05 | 2001-11-20 | リサーチ ディベロップメント ファンデーション | カフェイン酸フェネチル・エステル(CAPE)、CAPEの誘導体、カプサイシン(8―メチル―N―バニリル―6―ノネンアミド)及び樹脂分泌毒素による核転写ファクターNF―κBの抑制 |
JP2003524577A (ja) * | 1997-10-31 | 2003-08-19 | アーチ・デヴェロップメント・コーポレイション | 5α−還元酵素活性を調節するための方法及び組成物 |
Non-Patent Citations (7)
Title |
---|
CHEN J.H. ET AL: "Inhibitory effect of caffeic acid phenethyl ester on human leukemia HL-60 cells.", CANCER LETTERS., vol. 108, no. 2, 1996, pages 211 - 214, XP002992483 * |
DATABASE CAPLUS [online] "Anticancer activities of substituted cinnamic acid phenethyl esters on human cancer cell lines.", XP002992485, accession no. stn Database accession no. (2004:103875) * |
DATABASE CAPLUS [online] HUR G.M. ET AL: "Caffeic acid phenethyl ester inhibits the PKC-induced IL-6 gene expression in the synoviocytes of rheumatoid arthritis patients.", XP002992484, accession no. stn Database accession no. (2004:185683) * |
JOURNAL OF CHINESE PHARMACEUTICAL SCIENCE., vol. 12, no. 4, 2003, pages 184 - 187 * |
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY., vol. 7, no. 6, 2003, pages 353 - 368 * |
LEE Y.J. ET AL: "Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells.", CANCER LETTERS., vol. 153, no. 1-2, 2000, pages 51 - 56, XP002992480 * |
NANZANDO IGAKU DAIJITEN(GOKABAN).: "Gosei Retinoid.", 1998, NANZANDO CO.,LTD., XP002992486 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011178762A (ja) * | 2010-03-04 | 2011-09-15 | Pola Chemical Industries Inc | メラニン産生抑制剤 |
WO2021053493A1 (en) * | 2019-09-17 | 2021-03-25 | Enzene Biosciences Limited | Compositions for use in inhibiting src kinase and treating and preventing associated disorders |
CN114502153A (zh) * | 2019-09-17 | 2022-05-13 | 恩泽生物科学有限公司 | 用于抑制src激酶以及治疗和预防相关病症的组合物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005092322A1 (ja) | 2008-02-07 |
JP4904498B2 (ja) | 2012-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8389739B1 (en) | Modulators of retinoid-related orphan receptor gamma | |
US8389538B2 (en) | Rexinoid compound having alkoxy group | |
AU2007230991A1 (en) | Compounds and methods for treatment of disorders associated with ER stress | |
US20070238791A1 (en) | Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR modulators | |
US8071647B2 (en) | Method for treatment of adhesion of the intestines | |
JP2015180702A (ja) | 結腸癌発生を予防または低減する方法 | |
MX2011012559A (es) | Moduladores de lxr. | |
JP2019011343A (ja) | 選択的s1p1レセプターアゴニストを含む薬学的合剤 | |
US6605639B1 (en) | Ligands of nuclear receptor | |
JP2014076953A (ja) | レチノイドx受容体パーシャルアゴニスト化合物及びこのレチノイドx受容体パーシャルアゴニスト化合物を有効成分として含有する薬剤 | |
KR20190018486A (ko) | 암의 예방 및/또는 치료를 위한 화합물, 조성물 및 방법 | |
US6869959B1 (en) | Heterocyclic carboxylic acid derivatives | |
WO2004093910A1 (ja) | PPARδアゴニストによる脳神経変性疾患治療剤 | |
US20080139842A1 (en) | Medicament for preventive and/or therapeutic treatment of diseases with secretory disorder | |
WO2005092322A1 (ja) | Rar活性化を起こす天然化合物 | |
JP5885140B2 (ja) | Rxrパーシャルアゴニスト | |
JP2004531454A (ja) | PPARδ(β)のレギュレーターならびに肥満およびインスリン抵抗性の治療におけるその使用 | |
JP4886506B2 (ja) | 転写因子klf5の活性化抑制作用を有する医薬 | |
KR20100040725A (ko) | 간세포 증식 촉진작용을 갖는 의약 | |
JPH10251144A (ja) | インターロイキン−6産生阻害剤 | |
JPWO2010098125A1 (ja) | レチノイドx受容体パーシャルアゴニスト化合物 | |
KR20030086314A (ko) | 암 치료를 위한 레티노이드 수용체 리간드 및 선별된세포독성제의 상승적 조합 | |
JP2008074799A (ja) | 白内障の予防及び/又は治療のための医薬 | |
JPH1072345A (ja) | 9−シス−レチノイン酸−α−トコフェロールエステルを含有する白血病治療剤 | |
JPH07242541A (ja) | グルココルチコイド増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511413 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |